Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00654121 | Prevention of Clinical Onset of Type 1 Diabetes in High Risk First Degree Relatives | PHASE2 | COMPLETED | 112 | — | — | Feb 1, 2000 | Nov 1, 2007 | Apr 7, 2008 | 3 | Belgium |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | 56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily) |
| 2 | NO_INTERVENTION | - |
| Name | Type | Description |
|---|---|---|
| Actrapid HM | DRUG | 56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily) |
Inclusion Criteria: * Sibling/offspring of a Type 1 diabetic patient * in good general condition * age 5-39 years * fasting plasma glucose \<126 mg/dL AND an OGTT that is non-diabetic by 1997 ADA criteria (33): 1. Normal glycemia: * fasting plasma glucose \< 110 mg/dL and * 2 hour pla...